UK markets closed

Immunicum AB (publ) (IMMU.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
4.2000-0.0400 (-0.94%)
At close: 5:29PM CEST
Full screen
Previous close4.2400
Open4.2400
Bid4.1800 x 0
Ask4.2000 x 0
Day's range4.1400 - 4.2600
52-week range4.0400 - 10.4000
Volume99,841
Avg. volume335,688
Market cap837.484M
Beta (5Y monthly)0.97
PE ratio (TTM)N/A
EPS (TTM)-1.1220
Earnings date28 Oct 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est21.70
  • Globe Newswire

    Immunicum and the University Medical Center Groningen Receive a Grant from Health~Holland to Broaden Cancer Relapse Vaccine Development for Ovarian Cancer

    Press Release 8 September 2021 Immunicum and the University Medical Center Groningen Receive a Grant from Health~Holland to Broaden Cancer Relapse Vaccine Development for Ovarian Cancer Immunicum AB (publ; IMMU.ST) announced today that it has initiated a new research collaboration with the University Medical Center Groningen (UMCG), to explore novel treatment options for ovarian cancer based on the combination of Immunicum’s cell-based cancer vaccine platform with immune checkpoint inhibitors (C

  • Globe Newswire

    Immunicum Announces Participation in Multiple Upcoming Industry and Investor Events in September and October

    Press Release 27 August 2021 Immunicum Announces Participation in Multiple Upcoming Industry and Investor Events in September and October Immunicum AB (publ) today announced that it will participate in the following upcoming industry events and investor conferences in the period until 31 October. • 6th CAR-TCR Summit, August 30 – September 2, 2021Alex Karlsson-Parra, Chief Scientific Officer at Immunicum will be an expert speaker in a workshop at the CAR-TCR summit on 30 August 2021. He will pre

  • Globe Newswire

    Immunicum AB (publ) Interim Report April - June 2021

    Press Release 26 August 2021 Immunicum AB (publ) Interim Report April - June 2021 FINANCIAL SUMMARY FOR THE QUARTER APRIL - JUNE Net sales for the period amounted to - (-).Result for the quarter amounted to KSEK -31,278 (-12,625).Earning and diluted earnings per share totaled SEK -0,19 (-0,18). SIGNIFICANT EVENTS DURING THE QUARTER CORPORATE Immunicum presented an updated organization and corporate strategy overview at an investor event held on April 22, thereby completing the transition phase o